JAK2(V617F) mutation occurs in an homozygous status in 25-30% of patients with polycythemia vera (PV) and 2-4% with essential thrombocythemia (ET). Whether homozygosity associates with distinct clinical phenotypes is still under debate. This retrospective multicentric study considered 118 JAK2(V617F) homozygous patients (104 PV, 14 ET) whose clinical characteristics were compared to those of 587 heterozygous and 257 wild-type patients. Irrespectively of their clinical diagnosis, homozygous were older, displayed higher leukocyte count and hematocrit value at diagnosis, and presented larger spleen volume. Aquagenic pruritus was significantly more common among homozygous PV patients. JAK2(V617F) homozygosity associated to more frequent evolution into secondary myelofibrosis in both PV and ET. After adjustement for gender, age, leukocytes and previous thrombosis in a multivariate analysis, homozygous ET patients displayed a significantly higher risk of cardiovascular events (HR 3.97, CI 95% 1.34-11.7; p=0.013) than wild-type (HR=1.0) or heterozygous (HR=1.49). No significant association of JAK2(V617F) homozygosity with thrombosis risk was observed in PV. Finally, JAK2(V617F) homozygous patients were more likely to receive chemotherapy for control of disease. We conclude that JAK2(V617F) homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET.

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia / Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Rambaldi; Giovanni Barosi; Roberto Marchioli; Rosa Maria Marfisi; Guido Finazzi; Vittoria Guerini; Fabrizio Fabris; Maria Luigia Randi; Valerio De Stefano; Sabrina Caberlon; Agostino Tafuri; Marco Ruggeri; Giorgina Specchia; Vincenzo Liso; Edoardo Rossi; Enrico Pogliani; Luigi Gugliotta; Alberto Bosi; Tiziano Barbui. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 110:(2007), pp. 840-846.

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

VANNUCCHI, ALESSANDRO MARIA;ANTONIOLI, ELISABETTA;GUGLIELMELLI, PAOLA;BOSI, ALBERTO;
2007

Abstract

JAK2(V617F) mutation occurs in an homozygous status in 25-30% of patients with polycythemia vera (PV) and 2-4% with essential thrombocythemia (ET). Whether homozygosity associates with distinct clinical phenotypes is still under debate. This retrospective multicentric study considered 118 JAK2(V617F) homozygous patients (104 PV, 14 ET) whose clinical characteristics were compared to those of 587 heterozygous and 257 wild-type patients. Irrespectively of their clinical diagnosis, homozygous were older, displayed higher leukocyte count and hematocrit value at diagnosis, and presented larger spleen volume. Aquagenic pruritus was significantly more common among homozygous PV patients. JAK2(V617F) homozygosity associated to more frequent evolution into secondary myelofibrosis in both PV and ET. After adjustement for gender, age, leukocytes and previous thrombosis in a multivariate analysis, homozygous ET patients displayed a significantly higher risk of cardiovascular events (HR 3.97, CI 95% 1.34-11.7; p=0.013) than wild-type (HR=1.0) or heterozygous (HR=1.49). No significant association of JAK2(V617F) homozygosity with thrombosis risk was observed in PV. Finally, JAK2(V617F) homozygous patients were more likely to receive chemotherapy for control of disease. We conclude that JAK2(V617F) homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET.
2007
110
840
846
Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Rambaldi; Giovanni Barosi; Roberto Marchioli; Rosa Maria Marfisi; Guido Finazzi; Vittoria Guerini; Fabrizio Fabris; Maria Luigia Randi; Valerio De Stefano; Sabrina Caberlon; Agostino Tafuri; Marco Ruggeri; Giorgina Specchia; Vincenzo Liso; Edoardo Rossi; Enrico Pogliani; Luigi Gugliotta; Alberto Bosi; Tiziano Barbui
File in questo prodotto:
File Dimensione Formato  
333053.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 228.96 kB
Formato Adobe PDF
228.96 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/333053
Citazioni
  • ???jsp.display-item.citation.pmc??? 103
  • Scopus 385
  • ???jsp.display-item.citation.isi??? 356
social impact